Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy

Michael Joubert declares consultant and/or speaker fees and/or research support from Abbott, Amgen, AstraZeneca, Boehringer-Ingelheim, Dexcom, Glooko, Insulet, LifeScan, Lilly, Medtronic, NovoNordisk, Roche Diabetes, Sanofi, Tandem, and Ypsomed. Bertrand Cariou reports personal fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, and Ultragenyx, outside the submitted work. Simon Ducheix, Xavier Prieur and Alain Manrique have no competing interests to declare. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70012. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Figure S1. Anthropometric, metabolic and physiological outcomes after 6 weeks of treatment with dulaglutide or dapagliflozin. (A) Body weight; (B) random-fed blood glucose levels; (C) intraperitoneal glucose tolerance test (IPGTT) at 0, 15, 30, 60 and 120 min in SKO animals; (D) systolic blood pressure (SBP); (E) heart rate (HR). Data are presented as mean ± SEM. Statistically significant differences within animal groups (WT or SKO): *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (one-way ANOVA with post hoc multiple comparisons). Statistically significant differences between SKO PCB and WT PCB: †p < 0.05; ‡p < 0.01; §p < 0.001; ¶p < 0.0001 (one-way ANOVA with post hoc multiple comparisons). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.